Equities analysts expect Xencor, Inc. (NASDAQ:XNCR) to report earnings per share of ($0.27) for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Xencor’s earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.20). Xencor posted earnings per share of ($0.20) during the same quarter last year, which would indicate a negative year over year growth rate of 35%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, November 1st.

According to Zacks, analysts expect that Xencor will report full-year earnings of ($1.14) per share for the current year, with EPS estimates ranging from ($1.34) to ($0.92). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.62) per share, with EPS estimates ranging from ($2.02) to ($1.15). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Xencor.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 14.14%. The firm had revenue of $13.34 million during the quarter, compared to analyst estimates of $8.15 million.

A number of research firms recently commented on XNCR. Canaccord Genuity reiterated a “buy” rating and set a $36.00 price objective on shares of Xencor in a research report on Tuesday. Wedbush reiterated an “outperform” rating and set a $29.00 price objective on shares of Xencor in a research report on Friday, June 16th. Finally, Zacks Investment Research cut Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $29.33.

In other Xencor news, major shareholder John S. Stafford III purchased 1,500 shares of the stock in a transaction on Friday, June 16th. The stock was bought at an average price of $19.67 per share, for a total transaction of $29,505.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder John S. Stafford III purchased 6,000 shares of the stock in a transaction on Wednesday, June 28th. The stock was acquired at an average price of $19.94 per share, with a total value of $119,640.00. The disclosure for this purchase can be found here. Insiders sold a total of 34,766 shares of company stock valued at $739,408 in the last 90 days. 4.14% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the company. Norges Bank purchased a new stake in shares of Xencor during the fourth quarter worth about $15,601,000. Creative Planning boosted its stake in shares of Xencor by 2.7% in the first quarter. Creative Planning now owns 38,400 shares of the biopharmaceutical company’s stock worth $919,000 after buying an additional 1,000 shares during the last quarter. Marshall Wace North America L.P. purchased a new stake in shares of Xencor during the first quarter worth about $1,652,000. Goldman Sachs Group Inc. boosted its stake in shares of Xencor by 50.1% in the first quarter. Goldman Sachs Group Inc. now owns 262,439 shares of the biopharmaceutical company’s stock worth $6,277,000 after buying an additional 87,599 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. boosted its stake in shares of Xencor by 2.9% in the first quarter. Adams Diversified Equity Fund Inc. now owns 28,100 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 800 shares during the last quarter. Institutional investors and hedge funds own 74.12% of the company’s stock.

Shares of Xencor (NASDAQ XNCR) traded down 3.82% during midday trading on Wednesday, hitting $22.40. 178,930 shares of the company were exchanged. Xencor has a 52-week low of $18.45 and a 52-week high of $29.38. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of 63.46 and a beta of 2.14. The company has a 50-day moving average price of $22.46 and a 200-day moving average price of $23.07.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/xencor-inc-nasdaqxncr-expected-to-announce-earnings-of-0-27-per-share/1466781.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.